1-5 of 5
Donn Young
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Philip Binkley, Kenneth Chan, Jim Xiao, Daria Arbogast, Minden Collamore, Yasser Farra, Donn Young, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3997–4003.
https://doi.org/10.1158/1078-0432.CCR-05-2689
Published: 03 July 2006
View article titled, Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer

Tamila Kindwall-Keller, Gregory A. Otterson, Donn Young, Anterpreet Neki, Tamara Criswell, Gerard Nuovo, Richie Soong, Robert Diasio, Miguel A. Villalona-Calero
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1870–1876.
https://doi.org/10.1158/1078-0432.CCR-04-1727
Published: 08 March 2005
View article titled, Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer
Open the PDF for Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Donn Young, Hedy L. Kindler, Iain Webb, Barbara Kleiber, John Wright, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6111–6118.
https://doi.org/10.1158/1078-0432.CCR-04-0422
Published: 24 September 2004
View article titled, Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study

Charles F. Eisenbeis, Andrew Grainger, Beth Fischer, Robert A. Baiocchi, Lester Carrodeguas, Sameek Roychowdhury, Lei Chen, Amy L. Banks, Thomas Davis, Donn Young, Nicole Kelbick, Julie Stephens, John C. Byrd, Michael R. Grever, Michael A. Caligiuri, Pierluigi Porcu
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6101–6110.
https://doi.org/10.1158/1078-0432.CCR-04-0525
Published: 24 September 2004
View article titled, Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: <subtitle>A Preclinical and Phase I Study</subtitle>
Open the PDF for Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: <subtitle>A Preclinical and Phase I Study</subtitle> in another window
Journal Articles

Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer

Miguel A. Villalona-Calero, M. Guillaume Wientjes, Gregory A. Otterson, Steven Kanter, Donn Young, Anthony J. Murgo, Beth Fischer, Carrie DeHoff, Danny Chen, Teng-Kuang Yeh, SaeHeum Song, Michael Grever, Jessie L-S. Au
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3303–3311.
Published: 05 September 2003
View article titled, Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer in another window